Castle Biosciences Inc (NASDAQ:CSTL) price on current trading day, fall -3.02% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $31.19.
A look at the stock’s price movement, the close in the last trading session was $32.16, moving within a range at $30.6 and $32.6. The beta value (5-Year monthly) was 0.985 while the PE ratio in trailing twelve months stood at 156.03. Turning to its 52-week performance, $35.84 and $16.97 were the 52-week high and 52-week low respectively. Overall, CSTL moved -4.50% over the past month.
Castle Biosciences Inc’s market cap currently stands at around $847.20 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 80.58M for the company’s revenue for the quarter, with a low and high estimate of 75.4M and 84.49M respectively. The average forecast suggests up to a 21.86% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 326.31M, representing a 48.47% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CSTL is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend CSTL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CSTL’s current price about 1.81% and 0.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.14, while 7-day volatility ratio is 5.47% and 5.18% in the 30-day chart. Further, Castle Biosciences Inc (CSTL) has a beta value of 0.89, and an average true range (ATR) of 1.64. Analysts have given the company’s stock an average 52-week price target of $40.5, forecast between a low of $36 and high of $45. Looking at the price targets, the low is -15.42% off current price level while to achieve the yearly target high, price needs to move -44.28%. Nonetheless, investors will most likely welcome a -29.85% jump to $40.5 which is the analysts’ median price.
If we refocus on Castle Biosciences Inc (NASDAQ:CSTL), historical trading data shows that trading volumes averaged 0.3 over the past 10 days and 386.42K over the past 3 months. The company’s latest data on shares outstanding shows there are 27.98 million shares.
The 3.08% of Castle Biosciences Inc’s shares are in the hands of company insiders while institutional holders own 92.08% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.71 million on 2024-11-15, giving us a short ratio of 3.63. The data shows that as of 2024-11-15 short interest in Castle Biosciences Inc (CSTL) stood at 629.0 of shares outstanding, with shares short falling to 1.75 million registered in 2024-10-15. Current price change has pushed the stock 44.53% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CSTL stock continues to rise going into the next quarter.
